About: Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fragility fractures and the osteoporosis care gap in women: the Canadian Multicentre Osteoporosis Study Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 04 August 2010

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2010 (ast) наукова стаття, опублікована в серпні 2010 (uk) مقالة علمية نشرت في 04 أغسطس 2010 (ar) scientific article published on 04 August 2010 (en)
publication date	wds:Q37401913-9A58DD1D-0E96-4190-8808-3FBEDA989B42
publication date	2010-08-04 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37401913-D60BCD11-5B88-4947-BF33-9E3D2E8E2494
language of work or name	English
exact match	wds:Q37401913-E4F4ACC8-5CA8-4B45-A8FC-036D2ADB5C79
exact match	https://scigraph.springernature.com/pub.10.1007/s00198-010-1359-2
cites work	wds:Q37401913-03E4B423-12FD-4D19-86FD-5C3CEFD826D3 wds:Q37401913-072E846A-A9AF-4458-B119-78F9FF99927B wds:Q37401913-0FA42422-E3F6-481A-8BC2-63CDF5DEE710 wds:Q37401913-139E1FFC-4BA0-42CA-87EB-D155D65E76E9 wds:Q37401913-16050FA9-E0BD-4C90-955B-E4C8638E6B1E wds:Q37401913-289671DD-CC7B-45AD-879D-C5D04FCFFF2D wds:Q37401913-2D4060F2-BAD0-40F3-B766-7855F78C4912 wds:Q37401913-2FD3AA02-0FDE-4794-8899-2108B5D56810 wds:Q37401913-2FD77E5E-8419-43FD-9089-22DAACE5DEF0 wds:Q37401913-3BA49401-0EF0-4827-9DFC-424D74176C75 wds:Q37401913-41E0B4F1-5576-4D87-87D5-40B8F38739D0 wds:Q37401913-4751D093-7467-4200-816A-DB144D7553F8 wds:Q37401913-476C2F25-C022-4999-802F-CFA73C1E20BF wds:Q37401913-4BDC21F6-130E-44EE-BE18-9FB52371F185 wds:Q37401913-4EBE94C6-E6B3-48B4-A57D-8FCAAEE47319 wds:Q37401913-523BF571-AD46-4F27-AF56-F137EAFE8566 wds:Q37401913-53102737-5AB4-4151-905E-4CCB721F7304 wds:Q37401913-536F1D13-E61B-4288-966F-FC3585E5B490 wds:Q37401913-64ECA665-3657-40F5-A4C3-C5378F2DBCD0 wds:Q37401913-68D55B42-00B6-4874-97B7-3676A719ED10 wds:Q37401913-6AFFE22A-B2B3-4669-BA37-7BBF0983CBF8 wds:Q37401913-6E4FA3F0-F4B5-49B0-B07B-1D54FF32E03A wds:Q37401913-6F5C011B-70EF-401A-8A4A-5A9E23E7EAB3 wds:Q37401913-7B405F46-076B-44AE-805B-5E5FCE7DD585 wds:Q37401913-80AB9232-07AA-4FD7-838E-4090C95D87A6 wds:Q37401913-8A6504B8-D7EA-4C4B-9571-CB1C655C7949 wds:Q37401913-8F7E1F1B-1346-43E8-ABCD-E4C781C4FE03 wds:Q37401913-907C164D-460D-4146-865E-95F67DC3E8BA wds:Q37401913-ADFC7F22-F2C8-4632-BCE5-A8FCF58D939A wds:Q37401913-AE47BDAF-EE1A-4B6D-BDA4-9096AE6F8944 wds:Q37401913-B3CF43CD-4159-40D8-A8C0-372DE05CCFEB wds:Q37401913-C0792AA3-0693-47C8-808B-A662B36BA09B wds:Q37401913-C1ED3B39-5212-438D-BAE2-51260986AC7A wds:Q37401913-C24878E1-CC29-4198-8C19-ED3D0486E113 wds:Q37401913-D8A12ADE-F93C-4262-9C6C-CE869115FACA wds:Q37401913-DE15BDA8-B0D7-4056-B403-D91CF9B12C6C wds:Q37401913-E4E41D9C-1D8B-495A-8F87-A415E2F450E0 wds:Q37401913-E5906983-C4DD-468F-98B2-2EBAB465ED74 wds:Q37401913-F31A6127-1475-430C-9B97-CD9A85D0D06B wds:Q37401913-FA0CEFFD-7833-462A-8C8A-90B0261B8E2B
cites work	Burden of osteoporosis and fractures American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. Efficacy of risedronate on clinical vertebral fractures within six months. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review Fragility fractures and the osteoporosis care gap: an international phenomenon. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study The osteoporosis care gap in Canada Investigation and treatment of osteoporosis in patients with fragility fractures. Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study A meta-analysis of previous fracture and subsequent fracture risk Management of osteoporosis in postmenopausal women Pre-existing fractures and bone mass predict vertebral fracture incidence in women Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment Calcium and vitamin D intakes in an adult Canadian population Risedronate for the prevention and treatment of postmenopausal osteoporosis Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis Etidronate for treating and preventing postmenopausal osteoporosis. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women Low bone mineral density and fracture burden in postmenopausal women The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study The care gap in diagnosis and treatment of women with a fragility fracture Improvement in the undertreatment of osteoporosis following hip fracture. Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software